Figure 2.
Irinotecan oral bioavailability, F, is significantly higher (p < 0.001; Wilcoxon signed-rank test) in pediatric patients dosed daily with gefitinib, than those patients not receiving gefitinib treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.